Growth Drivers
What could change its growth trajectory, and what would confirm it?
Medline's growth depends on converting its $2.4 billion in total 2025 new customer signings into revenue, alongside full-year 2025 net sales of $28.4 billion, an 11.5% increase from $25.5 billion in full-year 2024.
Under multi-year contracts, Medline will supply medical-surgical products to more than 100 Ohio State Wexner system facilities and 11 Santiam Hospital locations. McKesson Medical-Surgical calls itself the nation's largest wholesale distributor of medical-surgical supplies and equipment.
Risk Factors
Which risks could break the thesis, and what would warn of them?
Medline's Asia-heavy sourcing turns U.S. tariff policy into a direct pretax cost, with tariffs expected to reduce income before taxes by $150 million to $200 million in fiscal 2026, as the majority of its products are sourced or manufactured in Asian nations, particularly China.
Medline's full year 2025 net income was $1.2 billion, a decrease of 3.6% from full year 2024, driven by higher costs of goods sold due to tariffs and higher operating costs. A net cash outflow related to legal settlements reduced the company's 2025 operating cash flow.
Product Overview
What does the product do for its buyer, and how is it delivered?
Medline's breadth of products, its own manufacturing, and its distribution infrastructure let it serve hospitals and other care settings across all points of care from a single supplier relationship. The company manufactures and distributes roughly 335,000 medical and surgical supplies, spanning gloves, masks, scalpels and wheelchairs, plus medical equipment for those settings in over 110 countries.
Its portfolio includes approximately 190,000 Medline Brand products across Surgical Solutions, Front Line Care and Laboratory & Diagnostics. The firm directs capital expenditure toward automation at its distribution centers and kitting manufacturing facilities.
